These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 31217201)

  • 1. A Phase I Dose Escalation Study of Once-Weekly Oral Administration of Docetaxel as ModraDoc001 Capsule or ModraDoc006 Tablet in Combination with Ritonavir.
    de Weger VA; Stuurman FE; Koolen SLW; Moes JJ; Hendrikx JJMA; Sawicki E; Thijssen B; Keessen M; Rosing H; Mergui-Roelvink M; Huitema ADR; Nuijen B; Beijnen JH; Schellens JHM; Marchetti S
    Clin Cancer Res; 2019 Sep; 25(18):5466-5474. PubMed ID: 31217201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A dose-escalation study of bi-daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir.
    de Weger VA; Stuurman FE; Hendrikx JJMA; Moes JJ; Sawicki E; Huitema ADR; Nuijen B; Thijssen B; Rosing H; Keessen M; Mergui-Roelvink M; Beijnen JH; Schellens JHM; Marchetti S
    Eur J Cancer; 2017 Nov; 86():217-225. PubMed ID: 29031170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration-resistant prostate cancer patients: A phase Ib study.
    Vermunt MAC; Robbrecht DGJ; Devriese LA; Janssen JM; Thijssen B; Keessen M; van Eijk M; Kessels R; Eskens FALM; Beijnen JH; Mehra N; Bergman AM
    Cancer Rep (Hoboken); 2021 Aug; 4(4):e1367. PubMed ID: 33709626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of docetaxel and ritonavir after oral administration of ModraDoc006/r in patients with prostate cancer versus patients with other advanced solid tumours.
    Vermunt MAC; van der Heijden LT; Hendrikx JJMA; Schinkel AH; de Weger VA; van der Putten E; van Triest B; Bergman AM; Beijnen JH
    Cancer Chemother Pharmacol; 2021 Jun; 87(6):855-869. PubMed ID: 33744986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Food on the Pharmacokinetics of the Oral Docetaxel Tablet Formulation ModraDoc006 Combined with Ritonavir (ModraDoc006/r) in Patients with Advanced Solid Tumours.
    Vermunt MAC; de Weger VA; Janssen JM; Lopez-Yurda MI; Keessen M; Thijssen B; Rosing H; Huitema ADR; Beijnen JH; Marchetti S
    Drugs R D; 2021 Mar; 21(1):103-111. PubMed ID: 33464545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Population Pharmacokinetic Model of Oral Docetaxel Coadministered With Ritonavir to Support Early Clinical Development.
    Yu H; Janssen JM; Sawicki E; van Hasselt JGC; de Weger VA; Nuijen B; Schellens JHM; Beijnen JH; Huitema ADR
    J Clin Pharmacol; 2020 Mar; 60(3):340-350. PubMed ID: 31595980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase 1 Dose-Escalation Study of Low-Dose Metronomic Treatment With Novel Oral Paclitaxel Formulations in Combination With Ritonavir in Patients With Advanced Solid Tumors.
    de Weger VA; Vermunt MAC; Stuurman FE; Burylo AM; Damoiseaux D; Hendrikx JJMA; Sawicki E; Moes JJ; Huitema ADR; Nuijen B; Rosing H; Mergui-Roelvink M; Beijnen JH; Marchetti S
    Clin Pharmacol Drug Dev; 2021 Jun; 10(6):607-621. PubMed ID: 33021083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancer.
    Vaishampayan UN; Keessen M; Dreicer R; Heath EI; Buchler T; Árkosy PF; Csöszi T; Wiechno P; Kopyltsov E; Orlov SV; Plekhanov A; Smagina M; Varlamov S; Shore ND
    Eur J Cancer; 2024 May; 202():114007. PubMed ID: 38518534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic evaluation of three oral formulations of docetaxel boosted with ritonavir: two single-drug formulations vs. a fixed-dose combination tablet.
    Moes JJ; Stuurman FE; Hendrikx JJ; Marchetti S; Huitema AD; Beijnen JH; Schellens JH; Nuijen B
    Drug Deliv Transl Res; 2013 Jun; 3(3):243-51. PubMed ID: 25788133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantification of the pharmacokinetic-toxicodynamic relationship of oral docetaxel co-administered with ritonavir.
    Yu H; Janssen JM; de Weger VA; Nuijen B; Stuurman RE; Marchetti S; Schellens JHM; Beijnen JH; Dorlo TPC; Huitema ADR
    Invest New Drugs; 2020 Oct; 38(5):1526-1532. PubMed ID: 32306204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumors.
    Oostendorp RL; Huitema A; Rosing H; Jansen RS; Ter Heine R; Keessen M; Beijnen JH; Schellens JH
    Clin Cancer Res; 2009 Jun; 15(12):4228-33. PubMed ID: 19509162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of loperamide on the pharmacokinetics and tissue disposition of ritonavir-boosted oral docetaxel therapy; a preclinical assessment.
    Loos NHC; Bui V; de Jong DH; Lebre MC; Rosing H; Beijnen JH; Schinkel AH
    Cancer Chemother Pharmacol; 2024 Jul; 94(1):79-87. PubMed ID: 38456955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001).
    Moes JJ; Koolen SL; Huitema AD; Schellens JH; Beijnen JH; Nuijen B
    Int J Pharm; 2011 Nov; 420(2):244-50. PubMed ID: 21907780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Saquinavir 500 mg film-coated tablets demonstrate bioequivalence to saquinavir 200 mg hard capsules when boosted with twice-daily ritonavir in healthy volunteers.
    Bittner B; Riek M; Holmes B; Grange S
    Antivir Ther; 2005; 10(7):803-10. PubMed ID: 16312177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase I study of the safety, pharmacokinetics and efficacy of navitoclax plus docetaxel in patients with advanced solid tumors.
    Puglisi M; Molife LR; de Jonge MJ; Khan KH; Doorn LV; Forster MD; Blanco M; Gutierrez M; Franklin C; Busman T; Yang J; Eskens FA
    Future Oncol; 2021 Jul; 17(21):2747-2758. PubMed ID: 33849298
    [No Abstract]   [Full Text] [Related]  

  • 16. A Phase 1 Study to Assess the Relative Bioavailability, Food Effect, and Safety of a Tablet Formulation of GSK2838232, a Novel HIV Maturation Inhibitor in Healthy Participants After Single and Repeated Doses.
    Johnson M; Jewell RC; Gan J; Dumont E; Burns O; Johns BA
    Clin Pharmacol Drug Dev; 2020 Nov; 9(8):972-977. PubMed ID: 32558338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and Toxicities of Oral Docetaxel Formulations Co-Administered with Ritonavir in Phase I Trials.
    Vermunt M; Marchetti S; Beijnen J
    Clin Pharmacol; 2021; 13():21-32. PubMed ID: 33536797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I safety and pharmacokinetic dose-escalation study of pilaralisib polymorph E, a phosphoinositide 3-kinase inhibitor in tablet formulation, in patients with solid tumors or lymphoma.
    Bechter OE; Dumez H; Costermans J; Punie K; Hsu K; Dedieu JF; Ghuysen AF; Francesconi E; Sharma J; Liu L; Schöffski P
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):83-90. PubMed ID: 27169794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors.
    Edelman G; Rodon J; Lager J; Castell C; Jiang J; Van Allen EM; Wagle N; Lindeman NI; Sholl LM; Shapiro GI
    Oncologist; 2018 Apr; 23(4):401-e38. PubMed ID: 29593099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors.
    Infante JR; Dees EC; Olszanski AJ; Dhuria SV; Sen S; Cameron S; Cohen RB
    J Clin Oncol; 2014 Oct; 32(28):3103-10. PubMed ID: 25113756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.